# Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

> **NCT05593328** · PHASE2 · COMPLETED · sponsor: **Cardiff Oncology** · enrollment: 23 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05593328
- **Lead sponsor:** Cardiff Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-17
- **Primary completion:** 2024-12-09
- **Final completion:** 2024-12-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593328, "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05593328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*